AI Accuracy is Determined by 'Data Quality' - AKT Health Launches Data Annotation Services Specialized for Pharma and Healthcare
AKT Health Co., Ltd. has launched 'Data Annotation as a Service' specialized for the pharmaceutical and healthcare sectors. Based on their proprietary 'HAIOps' framework, the service ensures high-quality AI training data by leveraging a specialized team with deep domain expertise to solve data preparation challenges in medical AI development.
📋 Article Processing Timeline
- 📰 Published: April 24, 2026 at 01:39
- 🔍 Collected: April 23, 2026 at 17:02
- 🤖 AI Analyzed: April 23, 2026 at 19:42 (2h 40m after Collected)
AKT Health Co., Ltd. (Headquarters: Tokyo; hereinafter "the Company") is pleased to announce the launch of its "Data Annotation as a Service" specialized for the pharmaceutical and healthcare domains. Based on the company's proprietary healthcare AI operational framework, "HAIOps (Healthcare AI Operations)," a specialized team with domain expertise will consistently ensure the data quality that determines the accuracy of Generative AI and machine learning models.
■ Why Data Annotation is Critical Now
The performance of AI models is heavily influenced by the "quality" rather than the "quantity" of training data. Especially in the medical and pharmaceutical fields, accurate understanding of clinical terms, context-aware labeling, and regulatory-compliant data management are indispensable.
From a market perspective, the importance is reflected in the numbers. The global AI training data market is projected to reach approximately $4.4 billion by 2026 and grow to $23.1 billion by 2034 (CAGR 22.9%). The Japanese market alone is expected to be worth approximately $280 million by 2026. (Source: Fortune Business Insights)
The Japanese healthcare analytics market recorded $2.4 billion in 2024 and is predicted to expand to $15.1 billion by 2033 (CAGR 19.8%). (Source: DataM Intelligence / EIN Presswire, February 2026)
The Ministry of Economy, Trade and Industry (METI) has expanded its spending in the semiconductor and AI sectors to approximately 1.23 trillion yen (approx. $7.9 billion) in the FY2026 budget, nearly four times the previous year. Furthermore, a goal for public-private investment in AI and semiconductors totaling 10 trillion yen by 2030 has been set, promoting industry-wide AI utilization, including in pharma and healthcare, as a national policy. (Source: Bloomberg, Dec 2025 / The Japan Times, Dec 2025 / NVIDIA Blog, Oct 2025)
A survey indicates that 67% of data scientists' time is spent on data preparation and cleaning rather than model building. (Source: Fivetran + Vanson Bourne, 2024)
While pharmaceutical companies and medical institutions in Japan are considering AI implementation, projects often stall at the stage of preparing training data. Our mission is to solve this challenge from the "upstream of data."
■ Service Overview
The "Data Annotation as a Service" provided by the company goes beyond simple labeling. Our specialized team provides end-to-end support from data design to annotation quality control and delivery.
Key Areas of Coverage:
- NLP annotation for pharmaceuticals and clinical documents (extraction and classification of medical terms, side effects, and indications)
- Classification and intent labeling of MR/physician behavior data (for promotion effect analysis)
- Sentiment analysis and theme extraction for patient surveys and questionnaires
- Structured data extraction from PDFs and images (approval application documents, academic papers, etc.)
- RLHF dataset construction for Generative AI evaluation (Good/Bad pairing and ranking)
■ Proprietary Framework "HAIOps" - A New Standard for Healthcare AI Operations
HAIOps (Healthcare AI Operations) is a proprietary healthcare-specific AI operational framework developed and proposed by the Company. It extends general MLOps (Machine Learning Operations) to address requirements unique to the medical and pharmaceutical fields, such as safety surveillance, regulatory compliance, and clinical validity. It consists of the following four layers:
1. Clinical Validation Layer: Double review by clinical experts, statistical management of inter-annotator agreement (Cohen's / Fleiss' Kappa), and benchmarking against gold standards.
2. Regulatory Compliance Layer: Electronic signatures compliant with 21 CFR Part 11, complete tracking of annotation history, and adherence to international standards such as CDISC, MedDRA, SNOMED CT, ICD, DICOM, and FHIR.
3. Safety Surveillance Layer: Escalation procedures for detecting adverse event signals, statistical monitoring of annotator judgment drift, and bias detection.
4. Performance Monitoring Layer: Project-specific dashboards, SLA management, and continuous feedback into SOPs.
■ Why Data Annotation is Critical Now
The performance of AI models is heavily influenced by the "quality" rather than the "quantity" of training data. Especially in the medical and pharmaceutical fields, accurate understanding of clinical terms, context-aware labeling, and regulatory-compliant data management are indispensable.
From a market perspective, the importance is reflected in the numbers. The global AI training data market is projected to reach approximately $4.4 billion by 2026 and grow to $23.1 billion by 2034 (CAGR 22.9%). The Japanese market alone is expected to be worth approximately $280 million by 2026. (Source: Fortune Business Insights)
The Japanese healthcare analytics market recorded $2.4 billion in 2024 and is predicted to expand to $15.1 billion by 2033 (CAGR 19.8%). (Source: DataM Intelligence / EIN Presswire, February 2026)
The Ministry of Economy, Trade and Industry (METI) has expanded its spending in the semiconductor and AI sectors to approximately 1.23 trillion yen (approx. $7.9 billion) in the FY2026 budget, nearly four times the previous year. Furthermore, a goal for public-private investment in AI and semiconductors totaling 10 trillion yen by 2030 has been set, promoting industry-wide AI utilization, including in pharma and healthcare, as a national policy. (Source: Bloomberg, Dec 2025 / The Japan Times, Dec 2025 / NVIDIA Blog, Oct 2025)
A survey indicates that 67% of data scientists' time is spent on data preparation and cleaning rather than model building. (Source: Fivetran + Vanson Bourne, 2024)
While pharmaceutical companies and medical institutions in Japan are considering AI implementation, projects often stall at the stage of preparing training data. Our mission is to solve this challenge from the "upstream of data."
■ Service Overview
The "Data Annotation as a Service" provided by the company goes beyond simple labeling. Our specialized team provides end-to-end support from data design to annotation quality control and delivery.
Key Areas of Coverage:
- NLP annotation for pharmaceuticals and clinical documents (extraction and classification of medical terms, side effects, and indications)
- Classification and intent labeling of MR/physician behavior data (for promotion effect analysis)
- Sentiment analysis and theme extraction for patient surveys and questionnaires
- Structured data extraction from PDFs and images (approval application documents, academic papers, etc.)
- RLHF dataset construction for Generative AI evaluation (Good/Bad pairing and ranking)
■ Proprietary Framework "HAIOps" - A New Standard for Healthcare AI Operations
HAIOps (Healthcare AI Operations) is a proprietary healthcare-specific AI operational framework developed and proposed by the Company. It extends general MLOps (Machine Learning Operations) to address requirements unique to the medical and pharmaceutical fields, such as safety surveillance, regulatory compliance, and clinical validity. It consists of the following four layers:
1. Clinical Validation Layer: Double review by clinical experts, statistical management of inter-annotator agreement (Cohen's / Fleiss' Kappa), and benchmarking against gold standards.
2. Regulatory Compliance Layer: Electronic signatures compliant with 21 CFR Part 11, complete tracking of annotation history, and adherence to international standards such as CDISC, MedDRA, SNOMED CT, ICD, DICOM, and FHIR.
3. Safety Surveillance Layer: Escalation procedures for detecting adverse event signals, statistical monitoring of annotator judgment drift, and bias detection.
4. Performance Monitoring Layer: Project-specific dashboards, SLA management, and continuous feedback into SOPs.